StockData
Silexion Therapeutics Corp logo

Silexion Therapeutics Corp (SLXN) stock

SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.98−0.68 (-25.56%)

Close on Nov 13, 2026Market cap $1.19MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$1.19M
P/E ratio
–
Price to sales
–
Price to book
0.40
Dividend yield
–
Free cash flow yield
-983.38%

Fundamentals

Net income
-$13.23M
EPS, diluted
$8.96
Free cash flow
-$11.74M
Book value per share
$16.05
Diluted shares
0M

Trading

Next earnings
Q3 FY2026, expected soon
Previous close
$2.66
Open
$2.55
Day's range
$1.82 – $2.62
Volume
103,470
Average volume (20 days)
307,709
Beta (5 years)
-0.36
52-week range
$0.14 – $777.06
RSI (14 days)
43.7
Volatility (1 year)
10497.3%
Relative volume
0.02×
WACC
7.6%

Market cap history

Month-end market cap since 2024, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodSLXNS&P 500DifferenceSLXN per yearS&P 500 per year
1 month+1025.0%-3.0%+1028.0 pts
3 months-82.1%-2.8%−79.3 pts
Year to date-99.6%+11.5%−111.1 pts
1 year-99.7%+13.5%−113.2 pts
3 years-99.9%+77.7%−177.6 pts-89.3%+21.1%
5 years-99.9%+72.6%−172.5 pts-73.3%+11.5%

Four years at a glance

Fiscal years 2022 to 2025 and trailing twelve months, USD

Operating income

-$13.52M

Net income

-$13.23M

EPS, diluted

–

Free cash flow

-$11.74M
Reported periodTrailing twelve months

Press releases

Releases Silexion Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Silexion Therapeutics

Biological Products, (No Diagnostic Substances)

Silexion Therapeutics Corp is a clinical-stage biotechnology company focused on oncology, specifically developing proprietary therapies for cancers driven by Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations. The company's technology silences oncogenes using chemically modified small interfering RNA (siRNA) constructs that prompt cancer cells to degrade messenger RNA. Its lead product candidate, SIL204, is a second-generation siRNA designed to halt the production of mutated KRAS proteins. SIL204 is administered both intratumorally and systemically via subcutaneous injection in combination with standard chemotherapy to treat patients with locally advanced pancreatic cancer.

Company profile, executives and history

Silexion Therapeutics stock: common questions

What is Silexion Therapeutics's stock price?

SLXN closed at $1.98 on Nov 13, 2026, down 25.56% on the day. Over the past 52 weeks it traded between $0.14 and $777.06.

What is Silexion Therapeutics's market cap?

Silexion Therapeutics was worth $1.19M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.

Does Silexion Therapeutics pay a dividend?

No. Silexion Therapeutics has not paid a cash dividend over the last twelve months.

When does Silexion Therapeutics report earnings next?

Silexion Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.

How has SLXN stock performed over the past year?

Including dividends, SLXN returned -99.7% over the past year, against +13.5% for the S&P 500.

Who are Silexion Therapeutics's competitors?

Companies most similar to Silexion Therapeutics by business, industry and size include CRDF, SLBT, PMCB, CRIS, BDTX.

See a number that looks wrong?